← Leaderboards
Rani E George
Dana-Farber Cancer Inst
$9,003,170
Attributed
$9,003,170
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $821.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,003,170 · 5
By mechanism
R01$7,727,549 · 3
K08$822,110 · 1
R21$453,511 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Timothy R Rebbeck$50,819,475
- Michael J Eck$25,871,961
- Mark M. Awad$878,255
- Christian Brendel$1,241,366
- Geoffrey Raymond Oxnard$230,333
Others in their field
Top investigators on “Neuroblastoma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Gregory H Reaman · National Childhood Cancer Foundation$84,462,747
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$58,436,699
- Larry Arthur$30,516,306
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
NeuroblastomaMalignant NeoplasmsCellsMediatingResistanceNeuroblastoma CellHigh RiskOncogenesMycn GeneTumorMutationTherapeutic TargetResponseSympathetic Nervous SystemApoptosisResistance MechanismGrowthInhibitor/AntagonistIn VitroCessation Of LifeNeoplastic CellDesignNeural CrestPrograms
Grant awards (29)
Cell lineage as an indicator of immune response in neuroblastoma$405,378
R01 · FY2025 · CA · contact PI
Cell lineage as an indicator of immune response in neuroblastoma$385,110
R01 · FY2024 · CA · contact PI
Translation initiation as a therapeutic target in neuroblastoma$194,750
R21 · FY2024 · CA · contact PI
Cell lineage as an indicator of immune response in neuroblastoma$397,270
R01 · FY2023 · CA · contact PI
Translation initiation as a therapeutic target in neuroblastoma$258,761
R21 · FY2023 · CA · contact PI
Cell lineage as an indicator of immune response in neuroblastoma$405,378
R01 · FY2022 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$413,844
R01 · FY2021 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$413,844
R01 · FY2020 · CA · contact PI
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers$407,748
R01 · FY2020 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$401,428
R01 · FY2019 · CA · contact PI
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers$395,514
R01 · FY2019 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$413,844
R01 · FY2018 · CA · contact PI
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers$407,748
R01 · FY2018 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$413,844
R01 · FY2017 · CA · contact PI
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers$407,748
R01 · FY2017 · CA · contact PI
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers$407,748
R01 · FY2016 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$363,125
R01 · FY2015 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$114,997
R01 · FY2015 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$352,231
R01 · FY2014 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$106,528
R01 · FY2014 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$341,338
R01 · FY2013 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$46,634
R01 · FY2013 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$363,125
R01 · FY2012 · CA · contact PI
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma$363,125
R01 · FY2011 · CA · contact PI
Zebrafish Peripheral Sympathetic Nervous System Development and Neuroblastoma$132,422
K08 · FY2008 · NS · contact PI
Zebrafish Peripheral Sympathetic Nervous System Development and Neuroblastoma$172,422
K08 · FY2007 · NS · contact PI
Zebrafish PSNS Development and Neuroblastoma$172,422
K08 · FY2006 · NS · contact PI
Zebrafish PSNS Development and Neuroblastoma$172,422
K08 · FY2005 · NS
Zebrafish PSNS Development and Neuroblastoma$172,422
K08 · FY2004 · NS